Catalent and Aegerion Partner on Launch of Newly FDA Approved JUXTAPID™

SOMERSET, N.J.--(BUSINESS WIRE)--
After a close 7-year partnership on clinical development, Catalent and
Aegerion will partner for international supply for newly FDA approved
JUXTAPID™ (lomitapide) capsules as an adjunct to a low-fat diet and
other lipid-lowering treatments in patients with homozygous familial
hypercholesterolemia (HoFH).

The productive partnership, which included close cooperation on
analytical development, clinical trial supply and manufacturing, will
now be expanded with Catalent as the exclusive supplier of JUXTAPID in 5
mg, 10 mg and 20 mg strengths for both US and European markets from
Catalent’s Kansas City, MO facility. Catalent will also support JUXTAPID
packaging and Qualified Person (QP) release from Catalent facilities in
Bolton and Swindon, UK for the European market.

"We are very happy that we partnered with Catalent for the JUXTAPID
product development," said Craig Fraser, President for U.S. and
International at Aegerion. “Their extensive oral solid clinical
development expertise, integrated offerings combined with the global
reach provided us a solid path to commercialization of this new,
important therapy.”

“The development of Aegerion’s JUXTAPID leveraged the wide array of
clinical development and supply expertise at Catalent,” commented Scott
Houlton, President of Development and Clinical Services at Catalent. “We
are delighted that Aegerion entrusted the development and reliable
global supply of this important orphan drug product to Catalent. We look
forward to a continued successful relationship with Aegerion, and to
helping to bring more products and better treatments to patients.”

Catalent Pharma SolutionsChris Halling, +44 (0) 7580-41073chris.halling@catalent.com

Source: Catalent Pharma Solutions